Mohamed Moussaoui

Dr. Mohamed Moussaoui

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMohamed Moussaoui
Mohamed Moussaoui
SBSoukayna Baammi
Soukayna Baammi
HSHatim Soufi
Hatim Soufi
MBMouna Baassi
Mouna Baassi
AAAchraf El Allali
Achraf El Allali
SBSaid Belaaouad
Said Belaaouad
Breast cancer remains a leading cause of cancer-related deaths among women globally, necessitating the development of more effective therapeutic agents with minimal side effects. This study explores novel 1,2,4-triazine-3(2H)-one derivatives as potential inhibitors of Tubulin, a pivotal protein in cancer cell division, highlighting a targeted approach in cancer therapy. Using an integrated computational approach, we combined quantitative structure–activity relationship (QSAR) modeling, ADMET profiling, molecular docking, and molecular dynamics simulations to evaluate and predict the efficacy and stability of these compounds. Our QSAR models, developed through rigorous statistical analysis, revealed that descriptors such as absolute electronegativity and water solubility significantly influence inhibitory activity, achieving a predictive accuracy (R2) of 0.849. Molecular docking studies identified compounds with high binding affinities, particularly Pred28, which exhibited the best docking score of − 9.6 kcal/mol. Molecular dynamics simulations conducted over 100 ns provided further insights into the stability of these interactions. Pred28 demonstrated notable stability, with the lowest root mean square deviation (RMSD) of 0.29 nm and root mean square fluctuation (RMSF) values indicative of a tightly bound conformation to Tubulin. The novelty of this work lies in its methodological rigor and the integration of multiple advanced computational techniques to pinpoint compounds with promising therapeutic potential. Our findings advance the current understanding of Tubulin inhibitors and open avenues for the synthesis and experimental validation of these compounds, aiming to offer new solutions for breast cancer treatment.

8 November 2024 in ACS Omega
Verified
Journal Article
Open access
MMMohamed Moussaoui
Mohamed Moussaoui
SBSoukayna Baammi
Soukayna Baammi
HSHatim Soufi
Hatim Soufi
MBMouna Baassi
Mouna Baassi
MSMohammed Salah
Mohammed Salah
SBSaid Belaaouad
Said Belaaouad
The epidermal growth factor receptor (EGFR) is part of a protein family that controls cell growth and development. Due to its importance, EGFR has been identified as a suitable target for creating novel drugs. For this research, we conducted a 2D-QSAR analysis on a set of 31 molecules derived from quinazoline, which exhibited inhibitory activity against human lung cancer. This investigation incorporated principal component analysis (PCA) and multiple linear regression (MLR), leading to the development of QSAR models with strong predictive capabilities (R 2 = 0.745, R 2_adj = 0.723, MSE = 0.061, R 2_test = 0.941, and Q 2_cv = 0.669). The reliability of these models was confirmed through internal, external, Y-randomization, and applicability domain validations. Leveraging the predictions from the QSAR model, we designed 18 new molecules based on the modifications at the N-3 and C-6 positions of the quinazoline ring, with electronegative substituents at these positions fostering optimal polar interactions and hydrophobic contacts within the ATP-binding site of EGFR, significantly enhancing the inhibitory activity against the lung cancer cell line. Subsequently, ADMET predictions were conducted for these 18 compounds, revealing outstanding ADMET profiles. Molecular docking analyses were performed to investigate the interactions between the newly designed molecules-Pred15, Pred17, Pred20, Pred21-and the EGFR protein, indicating high affinity of these proposed compounds to EGFR. Furthermore, molecular dynamics (MD) simulations were utilized to assess the stability and binding modes of compounds Pred17, Pred20, and Pred21, reinforcing their potential as novel inhibitors against human lung cancer. Overall, our findings suggest that these investigated compounds can serve as effective inhibitors, showcasing the utility of our analytical and design approach in the identification of promising therapeutic agents.

19 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
MMMohamed Moussaoui
Mohamed Moussaoui
MBMouna Baassi
Mouna Baassi
SBSoukayna Baammi
Soukayna Baammi
HSHatim Soufi
Hatim Soufi
MSMohammed Salah
Mohammed Salah
SBSaid Belaaouad
Said Belaaouad
The present study aims to investigate about the quantitative structure-activity relationship (QSAR) of a series of Thiazole derivatives reported as anticancer agents (hepatocellular carcinoma), using principally the electronic descriptors calculated by the DFT method and by applying the multiple linear regression method. The developed model showed good statistical parameters (R2 = 0.725, R2adj = 0.653, MSE = 0.060, R2test = 0.827, Q2cv = 0.536). The energy EHOMO orbital, electronic energy (TE), shape coefficient (I), number of rotatable bonds (NROT), and index of refraction (n) were revealed to be the main descriptors influencing the anti-cancer activity. Further, new Thiazole derivatives have been designed and their activities and pharmacokinetic properties have been predicted using the validated QSAR model. The designed molecules were then assessed to molecular docking (MD), and molecular dynamic (MDs) simulation accompanied by the calculation of the binding affinity using MMPBSA script according to 100 ns a simulation trajectory, to study both their affinity and their stability towards CDK2 as a target protein for the cancer disease treatment. This research concluded with the identification of four new CDK2 inhibitors which are A1, A3, A5, and A6 showing good pharmacokinetic properties. The MDs results revealed that the newly designed compound A5 remained stable in the active center of the discovered CDK2 protein, indicating its potential as a novel inhibitor for the treatment of hepatocellular carcinoma. The current findings may eventually contribute to the development of robust CDK2 inhibitors in the future.Communicated by Ramaswamy H. Sarma.

24 July 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
HSHatim Soufi
Hatim Soufi
MMMohamed Moussaoui
Mohamed Moussaoui
SBSoukayna Baammi
Soukayna Baammi
MBMouna Baassi
Mouna Baassi
MSMohammed Salah
Mohammed Salah
SBSaid Belaaouad
Said Belaaouad
In searching for a new and efficient therapeutic agent against Alzheimer's disease, a Quantitative structure-activity relationship (QSAR) was derived for 45 Flavonoid derivatives recently synthesized and evaluated as cholinesterase inhibitors. The multiple linear regression method (MLR) was adopted to develop an adequate mathematical model that describes the relationship between a variety of molecular descriptors of the studied compounds and their biological activities (cholinesterase inhibitors). Golbraikh and Tropsha criteria were applied to verify the validity of the built model. The built MLR model was statistically reliable, robust, and predictive (R2 = 0.801, Q2cv = 0.876, R2test = 0.824). Dreiding energy and Molar Refractivity were the major factors that govern the Anti-cholinesterase activity. These results were further exploited to design a new series of Flavonoid derivatives with higher Anti-cholinesterase activities than the existing ones. Thereafter, molecular docking and molecular dynamic studies were performed to predict the binding types of the designed compounds and to investigate their stability at the active site of the Butyrylcholinestérase BuChE protein. The negative and low binding affinity calculated for all designed compounds shows that designed compound 1 has a favorable affinity for the 4TPK. Moreover, molecular dynamics simulation studies confirmed the stability of designed compound 1 in the active pocket of 4TPK over 100 ns. Finally, the ADMET analysis was incorporated to analyze the pharmacokinetics and toxicity parameters. The designed compounds were found to meet the ADMET descriptor criteria at an acceptable level having respectable intestinal permeability and water solubility and can reach the intended destinations.Communicated by Ramaswamy H. Sarma.

17 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KAKhadijah Mohammed Al-Zaydi
Khadijah Mohammed Al-Zaydi
SBSoukayna Baammi
Soukayna Baammi
MMMohamed Moussaoui
Mohamed Moussaoui
Cancer remains one of the leading causes of death globally, presenting significant challenges to healthcare systems due to its complexity and the limitations of current therapeutic strategies. Despite advancements in anticancer drug development, monotherapies often fail to provide long-term efficacy due to the emergence of drug resistance. This resistance is primarily due to the activation of compensatory pathways in cancer cells, which allows them to bypass the effects of single-target therapies. To overcome this, targeting multiple key proteins simultaneously has emerged as a promising strategy to enhance therapeutic outcomes and address resistance mechanisms. In this study, 2-Phenylindole derivatives were explored as MCF7 breast cancer cell line inhibitors using 3D-QSAR modeling to design more effective compounds. The CoMSIA/ SEHDA model demonstrated high reliability (R² = 0.967) and a strong Leave-One-Out cross-validation coefficient (Q² = 0.814), further validated by external testing (R²Pred = 0.722). Six new compounds with potent inhibitory activity were designed, and their favorable ADMET profiles were confirmed. Molecular docking studies revealed that the newly designed compounds exhibited better binding affinities (−7.2 to −9.8 kcal/mol) to key cancer-related targets (CDK2, EGFR, and Tubulin) compared to the reference drug and the most active molecule (molecule 39) in the dataset. Additionally, 100 ns molecular dynamics simulations confirmed the stability of the best-docked complexes, highlighting their potential as promising candidates for anticancer drug development.

Verified
Journal Article
Open access
PDF file
MMMohamed Moussaoui
Mohamed Moussaoui
SBSoukayna Baammi
Soukayna Baammi
MBMouna BAASSI
Mouna BAASSI
SKSaid Kerraj
Said Kerraj
HSHATIM SOUFI
HATIM SOUFI
SBSaid Belaaouad
Said Belaaouad
A library of thirty-one quinazoline derivatives was assessed as potential inhibitors of epidermal growth factor receptor kinase (EGFR) using 3D-QSAR methods, namely Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Training and test sets were generated by aligning the molecules to the lowest-energy conformer of the most active compound. The optimized models exhibited strong statistical performance, with R2 values of 0.981 (CoMFA) and 0.978 (CoMSIA), and cross-validation coefficients (Q2) of 0.645 and 0.729, respectively. External validation confirmed their predictive power, yielding R2 values of 0.929 and 0.909. Guided by these models, eighteen new quinazoline candidates were designed and evaluated for drug likeness and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties using in silico approaches. Molecular docking and molecular dynamics simulations highlighted the binding features and stability of these derivatives, with compound Pred65 demonstrating superior affinity and stability compared to Erlotinib. Collectively, the study provides valuable insights for the optimization of quinazoline scaffolds as EGFR inhibitors, supporting the development of promising anticancer leads.